unitybiotechnology.com (UBX) - Long-Term Debt to Capital

Official company branding of unitybiotechnology.com (UBX)

Unity Biotechnology (UBX) develops innovative anti-aging treatments. This daily price action for the company on the GURU.Markets platform correlates with successes in joint and eye therapies, where the key metric is 0.00. The business relies on the creation of senolytics that eliminate worn-out cells. Amidst fierce competition with industry behemoths, the firm seeks to secure its patents and awaits the outcomes of medical trials.

UBX - Unity Biotechnology, Inc Long-Term Debt to Equity over the range 07/04/2022 - 07/19/2025

Analytical breakdowns and data insights for company Unity Biotechnology (UBX)

- price and consensus price forecast:
Share Price Unity Biotechnology Inc.|UBX - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Unity Biotechnology, Inc.|UBX - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Unity Biotechnology|UBX - Company Book Value|Capitalization to Book Value Ratio unitybiotechnology.com|UBX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Coefficient Unity Biotechnology|UBX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio unitybiotechnology.com|UBX - Company Total Debt|Debts to Book Value Unity Biotechnology, Inc.
Summary company analytics:UBX Unity Biotechnology Inc.
Signature product of Unity Biotechnology, Inc

This ratio determines the proportion of long-term liabilities relative to equity, measuring financial leverage and the degree of dependence on borrowed funds. For Unity Biotechnology (UBX), which is developing anti-aging senolytics, the analysis of long-term debt to equity reflects the cost of financing innovative research and development. High indicator values signal increased debt service risks, while a low level confirms the resilience of the business model. This ensures autonomy in the creation of drugs for treating age-related pathologies.

Competitor analysis

Long-Term Debt to Capital Ratio Tempus|Long-Term Debt to Capital QGEN|Long-Term Debt to Capital Isis Pharmaceuticals IONS|Long-Term Debt to Equity Ratio RGEN (Repligen Corporation)|aviditybiosciences.com - Long-Term Debt to Capital|CRISPR Therapeutics (CRSP) - Long-Term Debt to Equity|WGS - Long-Term Debt to Capital Ratio|Ultragenyx Pharma - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Beam Tx|Sarepta Therapeutics, Inc. (SRPT) - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio twistbioscience.com (TWST)|10x Genomics - Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital Intellia Therapeutics Inc NTLA|Long-Term Debt to Equity Ratio Stoke|Long-Term Debt to Capital Coefficient BioLife BLFS|WVE - Long-Term Debt to Capital|MAZE - Long-Term Debt to Equity|Sionna Therapeutics - Long-Term Debt to Capital|PRME (Prime Medicine Inc) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity TSHA (Taysha)|Long-Term Liabilities to Capital uniQure Pharma (QURE)|Long-Term Debt to Equity Ratio MeiraGTx Holdings plc|Long-Term Loans to Capital Ratio regenxbio.com (RGNX)|SLDB: Long-Term Debt to Capital|Long-Term Liabilities to Capital Ocugen Inc OCGN|PACB: Long-Term Debt to Capital|BNTC - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Design Therapeutics DSGN|RCKT (rocketpharma.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity 4D Molecular Therapeutics, Inc. (FDMT)|Long-Term Debt to Capital Ratio LXEO|Korro Bio, Inc. - Long-Term Debt to Equity|Long-Term Liabilities to Capital EDIT (Editas Corp)|Long-Term Debt to Equity Silence Therapeutics SLN|ProQR - Long-Term Debt to Equity|CDXS (Codexis Bio) - Long-Term Debt to Equity|SGMO - Long-Term Liabilities to Capital|Long-Term Debt to Capital NAUT (nautilus.bio)|Long-Term Indebtedness to Equity Metagenomi Therapeutics|Long-Term Debt to Equity Ratio DTIL (Precision BioSciences)|Long-Term Liabilities to Capital Generation Bio Corp (GBIO)|Long-Term Debt to Equity Ratio BOLD|Long-Term Debt to Capital exicuretx.com (XCUR)|Long-Term Debt to Capital Imunon IMNN|PHIO - Long-Term Debt to Equity|Mustang Bio Corp (MBIO) - Long-Term Debt to Equity Ratio|RNAZ - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital bionanogenomics.com|APDN (Applied DNA Sciences Inc) - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Bluebird Bio (BLUE)|Long-Term Debt to Capital Ratio ImmunoPrecise|Long-Term Debt to Capital OMGA|Long-Term Debt to Capital singulargenomics.com OMIC|Long-Term Debt to Equity Ratio RGLS (Regulus Therapeutics Inc.)|Syros Pharmaceuticals Inc. - Long-Term Debt to Capital|Codex DNA (TBIO) - Long-Term Debt to Equity|TCON - Long-Term Debt to Capital Ratio